In 20 years, it is estimated that the prevalence of Parkinson's disease (PD) will be doubled due to changed demographics (cf. increase of 630,000 PD patients in 2010 to 1.24 million people in 2040 in the United States) \[[@ref001]\]. A high proportion of these patients will develop cognitive dysfunctions during the disease (cf. cumulative prevalence of 83% for Parkinson's disease dementia (PDD) at 20-year follow-up \[[@ref002]\]), and it can be assumed that the proportion will even increase longitudinally due to population aging with more older patients.

Today, systematic reviews and meta-analyses demonstrate that cognitive training is safe and effective to enhance cognitive functions with small to large effect sizes depending on the functions trained and assessed \[[@ref004]\]. For example, two meta-analyses show significant cognitive training effects in executive functions as well as working memory which belong to the most vulnerable cognitive functions in PD \[[@ref005]\]. Lawrence and colleagues \[[@ref006]\] also found a positive impact on memory, while Leung et al. \[[@ref005]\] reported further improvements in processing speed. Both studies focused on cognitive training in PD patients without cognitive dysfunctions as well as mild cognitive symptoms. However, only few studies have examined neural correlates of training induced cognitive plasticity \[[@ref008]\]. Furthermore, effects on non-cognitive outcomes (e.g., neuropsychiatric symptoms, quality of life) are largely unclear as they were often not considered in randomized controlled trials (RCTs) so far. Also, rare information is available for the specific group of PD patients with (yet) no cognitive impairment or PD patients with mild cognitive impairment (PD-MCI) diagnosed (or excluded) according to established criteria. And even less is known regarding cognitive interventions in PDD patients \[[@ref011]\]. Up to now, there are no systematic reviews and meta-analyses examining the specific benefits of other cognitive approaches apart from cognitive training and cognitive rehabilitation (e.g., cognitive stimulation, reminiscence approaches). Hence, to achieve the long-term goal that effective cognitive interventions can be integrated into clinical routine, a lot of work has to be done in the next decades ([Table 1](#jpd-8-jpd181473-t001){ref-type="table"}).

###### 

Key ideas for the to do\'s with regard to cognitive interventions in Parkinson's disease for the next 20 years

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Development of interventions**
    ✓Standardized cognitive intervention manuals have to be developed for different approaches (e.g., cognitive training, cognitive rehabilitation, and cognitive stimulation) for patients with different cognitive stages (without cognitive impairment, PD-MCI, PDD).
    ✓ Further interventions targeting cognitive functions as one aspect (e.g., combined motor-cognitive trainings, mindfulness training) and including digital techniques (e.g., serious games, virtual reality) and further approaches supported by artificial intelligence have to be developed.
    ✓ Home-based variants of these interventions have to be developed.
  **Studies**
    ✓ Large multicenter RCTs which examine the efficacy and the best program characteristics (e.g., intensity and frequency of intervention, group versus individual training) of these different cognitive approaches have to be conducted
      •in PD patients with different cognitive stages (prodromal PD, PD, PD-SCI, PD-MCI, PDD),
      •in PD patients with different clinical profiles (e.g., regarding motor subtypes, neuropsychiatric symptoms),
      •in different settings (community-dwelling versus institutionalized),
      •considering more sensitive cognitive and non-cognitive outcomes including patient-centered outcomes and biomarkers,
      •including methods to analyze the underlying mechanisms of cognitive and neural plasticity induced by these interventions.
    ✓ Studies which examine the efficacy of multidomain lifestyle interventions in individuals with prodromal PD have to be conducted.
    ✓ Analysis of the cost-efficacy of these interventions in these groups has to be performed.
  **Clinical practice**
    ✓ Cognitive intervention manuals that are effective have to be made available for clinical practice.
    ✓ Effective cognitive interventions have to be integrated into clinical routine.
  **Broader concepts**
    ✓ The society -- and especially individuals at risk for neurodegenerative disease -- has to be educated with regard to the concept of cognitive reserve in order to promote a brain protecting lifestyle.
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: PD, Parkinson's disease; PDD, Parkinson's disease dementia; PD-MCI, Parkinson's disease with mild cognitive impairment; PD-SCI, Parkinson's disease with subjective cognitive impairment; RCT, randomized controlled trial.

Within the next 20 years⋯ 1.**Knowledge about and awareness of cognitive impairment in PD:** The knowledge about cognitive impairment in PD and its management has substantially improved. Clinicians are aware of the fact that cognitive impairment is a frequent and disabling symptom of PD. Cognitive change in medical history and screening for cognitive impairment is routinely conducted in all newly diagnosed PD patients and during the course of the disease.2.**Evidence-based cognitive interventions in clinical routine:** Evidence on the short- and long-term efficacy of standardized cognitive interventions in PD patients has been gathered with large multicenter RCTs, so that recommendations for clinical decision-making exist, and corresponding treatments with standardized manuals are available. Cost-efficacy studies, which are lacking so far, have been conducted. Cognitive interventions are implemented in clinical practice as an integral part of the multidisciplinary therapy regime. They are provided by qualified staff both in ambulant as well as long-term care settings. Staff trainings are widely available. The questions who will conduct the interventions (neuropsychologists, other?), and how patients get access have been clarified.3.**Consideration of heterogeneous patient groups and settings:** Clear evidence exists for the efficacy of cognitive interventions in PD patients in different cognitive stages including PD-MCI and PDD (mild, moderate, severe) diagnosed according to established criteria (cf. \[[@ref013]\]), both for community-dwelling individuals and institutionalized patients (e.g., hospitals, nursing homes), and with different potentially modifying neuropsychiatric symptom profiles (e.g., depression, apathy). Evidence has also been gathered for PD patients without objective cognitive impairment, but with a high risk to develop cognitive decline. These include patients with subjective cognitive impairment (SCI) (in analogy to SCI in pre-Alzheimer stages \[[@ref015]\]), but also PD patients without SCI who can be identified as having a high risk for cognitive decline by risk algorithms which have been further developed (based on current approaches, e.g., \[[@ref016]\]). Accordingly, specific recommendations and therapies for these groups of individuals and patients exist ([Fig. 1](#jpd-8-jpd181473-g001){ref-type="fig"}).4.**Dementia prevention starting in prodromal PD:** It is possible to identify prodromal PD more reliably \[[@ref018]\]. Cognitive changes in this disease stage, for which data are inconclusive yet \[[@ref019]\], have been investigated thoroughly in longitudinal studies, and trajectories to cognitive dysfunction are clear. Following large multicenter trials for prevention of dementia with individuals in prodromal stages of Alzheimer's disease examining the effect of multidomain lifestyle intervention including cognitive interventions and exercise (e.g., \[[@ref020]\]) but also management of cardio-vascular disease and other disease factors \[[@ref021]\] have also been conducted in patients with prodromal PD. Data exist regarding their efficacy to delay symptom onset with regard to motor and cognitive symptoms. Notably, today's view is that many reasons exist to be ambitious about prevention of dementia, and that cognitive interventions may play an important role \[[@ref021]\].5.**Relevant outcome measures:** Cognitive outcome measures (partly digital, more economic) that are much more sensitive to detect cognitive dysfunction and change of function and show few learning effects in PD have been developed and are used in studies \[[@ref023]\]. These may include, e.g., wearable devices or passive sensors that collect continuous, objective data during activities of daily living which may be more sensitive to subtle changes of function and are more realistic indicators of cognitive function than lab-based tests \[[@ref024]\]. Biomarkers for cognitive training effects have also been defined (e.g., parameters of structural and functional brain imaging \[[@ref025]\], EEG \[[@ref026]\], brain-derived neurotrophic factor (BDNF; \[[@ref027]\]) and other neurotrophic factors). Furthermore, studies have considered not only established cognitive or non-cognitive outcomes (such as neuropsychiatric symptoms like depression and apathy, activities of daily living, or quality of life), but also patient-centered outcomes (Patient Reported Outcome Measures (PROMs), Patient Reported Experience Measures (PREMS)) to assess those aspects that are most important for the individuals as well as subjective evaluation of intervention success (e.g., using training diaries to measure training motivation and to evaluate each session). Today, studies are just about to begin to include these important variables (e.g., a study conducting goal-oriented cognitive rehabilitation in PDD patients \[[@ref028]\]; recommendations for core outcome measures for dementia interventions partly based on patient involvement \[[@ref029]\]). Furthermore, in 2038 studies have provided information on which outcomes are decisive for patients in different cognitive stages and with different clinical (and maybe sociodemographic, genetic etc.) profiles.6.**Different approaches of cognitive interventions:** The spectrum of cognitive interventions that has been developed and evaluated for PD patients in different cognitive stages has broadened substantially ([Fig. 1](#jpd-8-jpd181473-g001){ref-type="fig"}). A clear-cut nomenclature for these interventions, elaborated by the international expert community, exists and is commonly used by scientists and clinicians. Interventions include cognitive training (i.e., standardized paper-and-pencil or computerized tasks provided in individual or group sessions targeting particular cognitive functions to improve or maintain these isolated functions \[[@ref030]\]; strategy training; often in combination with psychoeducation), cognitive rehabilitation (i.e., individualized approach targeting the patient's everyday context and developing strategies for improving or maintaining performance in activities of daily living \[[@ref030]\]), and cognitive stimulation (i.e., cognitively stimulating activities in small groups targeting the stabilization or improvement of global cognitive and social functioning primarily in patients with dementia \[[@ref030]\]; often in combination with reminiscence) and maybe further approaches. Those elements of these interventions that are most effective in enhancing cognition with transfer effects on everyday life and other relevant outcomes have been identified. Digital techniques including serious games (e.g., \[[@ref033]\]), virtual reality training \[[@ref034]\] and further to be defined interventions (e.g., neurofeedback training and brain-computer interface training) play an important role. Cognitive aspects and underlying neural mechanisms of mindfulness-based interventions, both aspects of which have only rarely been studied, but with promising results in, e.g., healthy elderly \[[@ref035]\] and, e.g., patients with non-PD dementia \[[@ref037]\], have been clarified, and their possible role as a cognitive intervention in PD is evident.7.**Motivating interventions:** Cognitive interventions exist that make fun and are motivating so that patients show high compliance in the long-term. This important goal has been achieved by involving patients in the development of cognitive interventions. More precisely, qualitative research (e.g., in form of focus groups), feasibility evaluations, and principles of user-centered design and content have consequently been integrated into the development process.8.**Home-based approaches:** Evaluated home-based interventions are common for those who like to do training at home, and especially for those in rural areas with limited access to ambulant therapies. By telemedicine techniques, training can easily be supervised and adapted to the individual cognitive level and training progress by experts. As valid and reliable digital cognitive tests are available, training progress can be monitored on a regular basis.9.**Clear therapy recommendations:** Data exist which inform clinicians about the best frequency and intensity for different forms of cognitive interventions in PD patients in different cognitive stages. The question how often (once, once a year, more frequently -- or continuously?) training programs have to be conducted and what booster training adds to benefits \[[@ref038]\] can be answered. Regarding long-term effects, the question whether cognitive interventions (or which intervention type in which PD patients) only attenuate or rather delay the trajectory to cognitive decline has been answered \[[@ref038]\].10.**Cognitive-motor-interplay:** The interplay between cognitive and motor functions as well as specific symptoms such as freezing \[[@ref039]\] in PD has been defined concisely \[[@ref040]\]. Effects of cognitive training on these outcomes, which are currently under discussion \[[@ref041]\], are clear.11.**Combined approaches:** Different forms of combined motor-cognitive trainings have been thoroughly studied and are available as standard interventions. Data on the efficacy of further combined interventions are also available and have been transferred into clinical practice accordingly. They may include cognitive interventions with other therapies with the potential to enhance cognition (e.g., playing an instrument \[[@ref043]\], other creative therapies), but also cognitive training or brain interface trainings in combination with brain stimulation techniques (tDCS and TMS) \[[@ref006]\] or set-ups of deep brain stimulation targeting cognitive functions according to neurofeedback. Furthermore, the additional benefit of combining cognitive interventions with antidementia drugs is clear (which has exclusively been shown in non-PD patients with dementia so far, e.g., \[[@ref044]\]), and has led to adapted therapy regimes. Assumed that disease-modifying drugs are available, data has also been gathered with regard to combining these with non-pharmacological interventions (among them cognitive approaches) in patients in early phases of the disease. The role of potential pharmacological cognitive enhancers in the prevention and therapy of cognitive dysfunction in PD has been investigated \[[@ref045]\].12.**Mechanism and prediction models:** Underlying mechanisms of neural and cognitive plasticity induced by cognitive and combined interventions in PD patients have been investigated multimethodically including, e.g., functional and structural brain imaging techniques, electrophysiological methods, and blood analysis. Furthermore, prediction analyses have identified factors that influence the intervention benefit. These may include sociodemographic variables (e.g., age, education, gender), clinical parameters (e.g., disease duration and severity, motor subtype, medication, comorbidities), severity of cognitive dysfunction and cognitive profile (e.g., amnestic versus non-amnestic single versus multiple domain PD-MCI), and genetics (e.g., carriers versus non-carriers of ApoE, GBA, MAPT). This knowledge has led to more targeted and efficient interventions.13.**Personalized interventions:** Cognitive (and combined) interventions have entered the era of personalized medicine. This means that interventions are tailored to the individual (cognitive/motor/genetic etc.) profile and preferences (e.g., group versus individual training, digital versus paper and pencil training, gaming versus classical training), probably supported by machine learning techniques. Compiling an individual training plan including cognitive or combined intervention is easy as it follows an evidence-based algorithm. Digital tools are available for the clinician in which local facilitators of these interventions are listed and can directly be contacted. Fig.1Possible scheme for cognitive approaches in Parkinson's disease in 20 years. Abbreviations: PD, Parkinson's disease; PDD, Parkinson's disease dementia; PD-MCI, Parkinson's disease with mild cognitive impairment; PD-SCI, Parkinson's disease with subjective cognitive impairment.

More generally, the awareness of the concept of cognitive reserve for PD patients \[[@ref046]\] has increased substantially, and the broader concept of cognitive reserve and possibilities for the prevention of age-related cognitive decline and dementia is acknowledged in the population, promoted by research driven society based campaigns (e.g., <https://www.wezijnzelfhetmedicijn.nl/> in the Netherlands), so that more people wittingly follow a healthy and brain protecting lifestyle including more mental, physical and social activities and a healthy diet.
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